# Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

> **NCT04057365** · PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 15 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** DKN-01

## Key facts

- **NCT ID:** NCT04057365
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-07
- **Primary completion:** 2022-09-25
- **Final completion:** 2022-09-25
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Based on a Simon 2-stage design, this study did not meet response criteria to proceed to stage 2.
- **Last updated:** 2025-08-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04057365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04057365, "Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04057365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*